Thermo Fisher Plummets Amid Record High Trading Volume Surging to 1.62B Ranking 73rd in Market Activity

Thermo Fisher Scientific (TMO) closed at $477.28 on July 31, 2025, reflecting a 2.01% decline amid a 31.18% surge in trading volume to $1.62 billion, ranking 73rd in market activity. Institutional investors, including Bristol Gate Capital Partners and Pictet Asset Management, increased holdings in the first quarter, while Barclays analyst Luke Sergott raised the price target to $490 from $450, citing long-term potential. TD Cowen maintained a Buy rating despite lowering its price target to $550, emphasizing modest Q2 growth and market dynamics.

The company reported Q2 revenue of $10.85 billion, a 3% year-over-year increase, driven by biopharma services and life sciences solutions. However, Baron Health Care Fund’s Q2 letter highlighted TMO as a top holding while expressing preference for AI stocks, suggesting perceived higher upside potential. Analysts noted mixed signals, with a sell signal from a recent pivot top and a buy signal from the 3-month MACD, reflecting short-term volatility amid a broader upward trend.

A backtested strategy of purchasing top 500 high-volume stocks and holding for one day generated a 166.71% return from 2022 to 2025, outperforming the benchmark by 137.53%. This approach leveraged liquidity-driven momentum, as seen in stocks like TMO, though its future efficacy may depend on evolving market structures and liquidity patterns.